A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer

Trial Profile

A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Carboplatin; Docetaxel; Pertuzumab; Trastuzumab
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KRISTINE
  • Sponsors Roche
  • Most Recent Events

    • 22 Jun 2018 This trial has been completed in Belgium (End date: 2018-05-29), according to European Clinical Trials Database.
    • 29 May 2018 This trial has been completed in Spain on 30-Apr-2018, according to European Clinical Trials Database.
    • 25 Apr 2018 Planned End Date changed from 31 Mar 2018 to 31 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top